Schlagwort: Thomas Meier
Organoids and organs on chips – an emerging biotech/pharma business
Organoids or organs-on-chips (OoCs) are two types of three-dimensional tissue culture systems amenable for the study of complex human physiological functions. Regulators increasingly recognize...
How to access the public US capital market without an IPO?
European medtech and biotech companies might find engaging in a reverse merger (RM) with a US-based Nasdaq-listed company to be an appealing alternative to...
Santhera: Fortschritte bei der Behandlung von Muskelschwund
Santhera Pharmaceuticals ist ein Schweizer Spezialitätenpharmaunternehmen, das sich auf die Entwicklung und Vermarktung von innovativen Medikamenten für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem...
The potential of AI in drug discovery
Tools and methods derived from artificial intelligence (AI) will revolutionize drug discovery processes by identifying novel molecular targets, increasing the probability of success in...